<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140123</url>
  </required_header>
  <id_info>
    <org_study_id>ZSP1601-18-02</org_study_id>
    <nct_id>NCT04140123</nct_id>
  </id_info>
  <brief_title>Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Dose-increasing, Placebo-controlled，Multi-dose, 28-day Continuous Administration Phase Ib/IIa Clinical Trial to Evaluate the Tolerability, Efficacy, and PK of ZSP1601 in Patients With Nonalcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Raynovent Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Raynovent Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomized, placebo-controlled study to explore the safety, tolerability PK
      characteristics and early efficacy of ZSP1601 tablets in patients with non-alcoholic
      steatohepatitis (NASH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE) following oral doses of ZSP1601 and placebo.</measure>
    <time_frame>Initiation of study treatment (Day 1) up to 2 weeks post-treatment.</time_frame>
    <description>severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI-PDFF</measure>
    <time_frame>Baseline and Day 28.</time_frame>
    <description>liver fat content with Magnetic resonance imaging proton density fat fraction (MRI‐PDFF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α</measure>
    <time_frame>Baseline and Day 28.</time_frame>
    <description>Tumor necrosis factor alpha level in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>Baseline and Day 28.</time_frame>
    <description>serum Alanine Aminotransferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>Baseline and Day 28.</time_frame>
    <description>serum Aspartate Aminotransferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>The time after dosing when Cmax occurs (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>Maximum Contentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2z</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>t1/2z is defined as the time to decline half of the drug concentration in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac of Cmax</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>Rac of ZSP1601 Peak Plasma Concentration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DF of ZSP1601 at steady status</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>Multiple-dose plasma PK parameter: DF of ZSP1601 at steady status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast（AUC0-t）</measure>
    <time_frame>Baseline (0h) and day 14</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac of AUC</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>RAC of ZSP1601 Area under the plasma concentration versus time curve at steady state</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AUC(inf)</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>Area under the curve extrapolated until time is infinity (AUCinf)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Non-Alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>ZSP1601-Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP1601-50mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601-Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP1601-50mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601-Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP1601-100mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601</intervention_name>
    <description>ZSP1601 tablets be taken orally for 28 days.</description>
    <arm_group_label>ZSP1601-Dose 1</arm_group_label>
    <arm_group_label>ZSP1601-Dose 2</arm_group_label>
    <arm_group_label>ZSP1601-Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601 Placebo</intervention_name>
    <description>Subjects will receive matching placebo of ZSP1601</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>ZSP1601-Dose 1</arm_group_label>
    <arm_group_label>ZSP1601-Dose 2</arm_group_label>
    <arm_group_label>ZSP1601-Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects are required to meet the following criteria in order to be included in the
             trial:

               1. Signature signed informed consent before the trial, and fully understood the
                  content, process and possible adverse reactions.

               2. Subjects must be willing and able to adhere to the visit schedule and protocol
                  requirements and be available to complete the study.

               3. Subjects(including partners)have no gestation plans and must use reliable methods
                  of contraception during the study and until 6 months following the last dose of
                  investigational product.

               4. Male and female subjects aged 18-65 (including 18 and 65).

               5. B ultrasound confirmed fatty liver.

               6. NASH diagnosis or NASH phenotypic diagnosis.

               7. Liver fat ≥10% at baseline (MRI-PDFF)

        Exclusion Criteria:

          -  Eligible subjects must not meet any of the following exclusion criteria:

               1. Excessive drinking for 3 consecutive months within 1 year before screening.

               2. Allergic constitution.

               3. Subjects who donated blood or bleeding profusely(&gt; 400 mL)in the 3 months
                  preceding study screening.

               4. Subjects having a history of bariatric surgery or preparing for bariatric surgery
                  recently.

               5. Subjects having a history of liver transplantation or plans for liver
                  transplantation

               6. Any diseases that increase the risk of bleeding, such as hemorrhoids, acute
                  gastritis or gastric and duodenal ulcers.

               7. Liver biopsy indicates cirrhosis or previous clinical diagnosis of cirrhosis.

               8. Type 1 diabetes mellitus.

               9. Uncontrolled type 2 diabetes mellitus (HbA1c≥8.0%)。

              10. Any clinically significant abnormality upon physical examination or in the
                  clinical laboratory tests, history or presence of other causes of liver
                  disease,but not limited to above disorders: hepatitis b or hepatitis c virus
                  (HCV) infection and chronic alcoholic liver disease, drug-induced liver disease,
                  autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis,
                  Wilson 's disease, alpha 1 - antitrypsin deficiency, liver, obvious abnormal
                  liver function (ALT and AST acuity 5 x ULN or TBIL acuity 1.5 x ULN), etc.

              11. Dysphagia or any medical history in gastrointestinal that interferes with the
                  absorption of drugs.

              12. History of having any special food(including dragon
                  fruit,mango,grapefruit,etc.),strenuous exercises,or other factors may interfere
                  with the absorption, distribution, metabolism, or excretion of drug within 2
                  weeks prior to screening.

              13. Participated in another clinical research study and received any investigational
                  products within 3 months prior to dosing.

              14. Presence of clinically significant abnormalities in ECG or QTcB&gt;450ms in males,or
                  QTcB&gt;470ms in females.

              15. HIV positive.

              16. Clinically significant nephropathy or renal dysfunction, blood creatinine
                  &gt;1.5×ULN, eGFR&lt; 60 mL/min/1.73m2 [calculation formula: Ccr:(140-age)× weight (kg)
                  /0.818×Scr(mumol /L), female ×0.85].

              17. Platelet count &lt;100×109/L.

              18. Antinuclear antibody (ANA) confirmed positive and clinically significant.

              19. Abnormal TSH with clinical significance.

              20. Female during pregnancy and lactation or positive serum pregnancy test.

              21. Patients with contraindication of MRI scan.

              22. Take any product contains alcohol within 24 hours prior to dosing.

              23. Have chocolate, any food or beverage that contains caffeine or xanthine within 24
                  hours prior to dosing.

              24. Positive for urine drug screening or history of substance abuse for a period of 5
                  consecutive years before screening.

              25. Any acute illness or concomitant medication from screening to first dosing.

              26. As judged by the researcher, it is not suitable to join the clinical researcher.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junqi Niu, Doctor</last_name>
      <phone>13756661205</phone>
      <email>junqiniu@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

